Hemab Therapeutics (COAG) reported a Q2 net loss Tuesday of $0.80 per diluted share, narrowing from a $12.91 loss per share a year earlier.
One analyst polled by FactSet expected a $0.56 loss per share.
No revenue was reported for the period.
Hemab Therapeutics shares were down 1.7% premarket Tuesday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments